Evidence / Shep et al. · 2019
Open-label comparison of curcumin and diclofenac
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Randomized, open-label, parallel active-comparator trial.
- Product relevance
- Ingredient research involving turmeric extracts or curcuminoids.
- Sample or population
- 139 participants with knee osteoarthritis.
- Studied dose
- One 500 mg capsule of the studied curcumin formulation three times daily or diclofenac 50 mg twice daily.
- Duration
- 28 days.
- Finding
- Pain and knee outcome scores showed no statistically significant between-group difference. Adverse effects were reported in 13% of the curcumin group and 38% of the diclofenac group.
- Limitations
- Participants and investigators knew the assigned treatment. The trial was short and had no placebo arm. A nonsignificant difference does not establish equivalence.
- Study quality
- The outcomes, study design and limitations were reviewed. No formal risk-of-bias rating was assigned for this summary.
- Funding and disclosures
- The authors declared no competing interests and acknowledged that Arjuna Natural provided the curcumin capsules. The paper lists the funding field as not applicable.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.
Licensed product information
High-Potency Turmeric Extract · NPN 80143038
Source of (an) antioxidant(s)/Provides (an) antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals.